American Journal of Epidemiology Advance Access published online on March 1, 2006
American Journal of Epidemiology, doi:10.1093/aje/kwj080
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland
* To whom correspondence should be addressed. The lignan enterolactone produced by the intestinal microflora from dietary precursors has been hypothesized to protect against coronary heart disease. The present study examined the association between serum enterolactone concentration and the risk of coronary heart disease. A prospective case-cohort study was conducted among male smokers randomized to receive a placebo supplement in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (1986-1999). Serum enterolactone concentrations were measured by the gas chromatography-mass spectrometry method in serum collected at trial baseline from 340 men diagnosed with nonfatal myocardial infarction (n = 205) or coronary death (n = 135) during follow-up and from the randomly selected subcohort of 420 subjects. The classic risk factors-adjusted rate ratios for all coronary heart disease events in increasing quintiles of enterolactone were 1.00 (referent), 0.85 (95% confidence interval (CI): 0.51, 1.43), 0.59 (95% CI: 0.35, 1.00), 0.69 (95% CI: 0.40, 1.16), and 0.63 (95% CI: 0.33, 1.11), and the ptrend was 0.07. For the highest versus the lowest quintile of enterolactone, the rate ratios for nonfatal myocardial infarction and coronary death were 0.67 (95% CI: 0.37, 1.23; ptrend = 0.10) and 0.57 (95% CI: 0.26, 1.25; ptrend = 0.18), respectively. In conclusion, only weak support for the association between serum enterolactone concentration and coronary heart disease was found.
Received March 22, 2005
Accepted October 20, 2005
ORIGINAL CONTRIBUTIONS
Serum Enterolactone Concentration and the Risk of Coronary Heart Disease in a Case-Cohort Study of Finnish Male Smokers
Annamari Kilkkinen 1 *,
Iris Erlund 2,
Mikko J. Virtanen 1,
Georg Alfthan 2,
Kari Ariniemi 3,
and
Jarmo Virtamo 1
2 Department of Health and Functional Capacity, National Public Health Institute, Helsinki, Finland
3 Department for Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland
Annamari Kilkkinen, E-mail: annamari.kilkkinen{at}ktl.fi
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
I. Erlund, R. Koli, G. Alfthan, J. Marniemi, P. Puukka, P. Mustonen, P. Mattila, and A. Jula Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol Am. J. Clinical Nutrition, February 1, 2008; 87(2): 323 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. M. Peeters, N. Slimani, Y. T. van der Schouw, P. B. Grace, C. Navarro, A. Tjonneland, A. Olsen, F. Clavel-Chapelon, M. Touillaud, M.-C. Boutron-Ruault, et al. Variations in Plasma Phytoestrogen Concentrations in European Adults J. Nutr., May 1, 2007; 137(5): 1294 - 1300. [Abstract] [Full Text] [PDF] |
||||

